Q-omics provides the consensus-scored MED17 profile across patient tissues and cancer cell-line models. MED17 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MED17 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MED17 RNA expression shows 20,613 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where MED17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED17 survival associations across molecular data types. MED17 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED17 RNA expression–survival associations across cancer types. High MED17 expression shows unfavorable associations in LIHC, BRCA and ACC, but favorable associations in KIRC, UCS and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MED17 RNA expression.
This table summarizes MED17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MED17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED17 shows higher tumor expression in HNSC, KIRC, LUAD, LIHC, COAD and STAD. The HNSC box plot shows higher MED17 RNA expression in tumor versus normal tissue (log2 FC = +0.676, t-test p < 0.001).
This table shows molecular features associated with MED17 in patient tissues and cancer cell lines. In patient samples, MED17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
